Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study

Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a standard first-line treatment for advanced EGFR-mutated NSCLC patients. Factors associated with symptoms and quality of life (QOL) improvements have not been investigated. Methods: We conducted a multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yu-Feng, Huang, Wen-Tsung, Liu, Tu-Chen, Shieh, Jiunn-Min, Chian, Chih-Feng, Wu, Ming-Fang, Chang, Chih-Cheng, Lin, Ching-Hsiung, Ko, Jen-Chung, Lin, Chia-Mo, Hsia, Te-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692623/
https://www.ncbi.nlm.nih.gov/pubmed/31417660
http://dx.doi.org/10.7150/jca.30507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692623/
https://www.ncbi.nlm.nih.gov/pubmed/31417660
http://dx.doi.org/10.7150/jca.30507

Ejemplares similares